A recent study suggests that a blood test could potentially diagnose Alzheimer's disease with high accuracy, offering a promising breakthrough in early detection. The test, known as ALSPATH, has the potential to revolutionize Alzheimer's diagnosis by providing a more accessible and routine method of testing.
The conventional methods of diagnosing Alzheimer's involve brain scans or spinal taps to detect the accumulation of proteins called beta amyloid and tau, which are characteristic indicators of the disease. However, these methods are not easily accessible to everyone due to their cost and invasiveness. Brain scans can be expensive and involve radiation, while spinal taps are intrusive and financially burdensome.
